A Phase 2 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Pulmonary Diseases and Neoplasms, Lung, sponsored by Sanofi. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-10.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Lung Neoplasms by Sanofi — 1 open to participants now, 1 under way, none of them phase 3. Lung Neoplasms · Sanofi.
Among the 23 studies in Lung Neoplasms by Sanofi, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2006, is one of 7 in phase 2, and was the 6th registered.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →1 of the 23 studies in Lung Neoplasms by Sanofi is open now, in 2 countries. Recruiting first, the newest first:
Blueprint Medicines Corporation · Sites in United States, Spain
Ages 18+
By country, each count listing its studies:
Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 8
First in 2000; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.
Median enrollment 132 across the 20 interventional studies, 279 across the 1 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Lung Neoplasms by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy and safety of aflibercept in the treatment of participants with advanced chemoresistant non-small cell lung adenocarcinoma (NSCLA).
Primary objective:
Secondary objective:
This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation.
In addition, both Response Evaluation Criteria In Solid Tumors (RECIST) and Modified Response Evaluation Criteria In Solid Tumors (mRECIST) were used to assess tumors. Where as RECIST criteria only consider the longest diameter of the tumors for calculations pertaining to changes in tumor size, mRECIST assessments also account for the differences in the cavities of lesions observed in non-small-cell lung cancer (NSCLC). Responses based on RECIST and mRECIST are reported.
The study included :
Withdrawal criteria that led to treatment discontinuation were:
After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
This study's enrollment of 98 is above the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Compared within Lung Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who met the following criteria were eligible for the study.
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with metastatic non-small-cell lung adenocarcinoma administered 4.0 mg/kg Aflibercept every 2 weeks until a study withdrawal criterion was met.
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks. Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).
OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the IRC, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.
Time frame: up to 2.5 years from initial treatment
Confirmed Objective Response Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Investigator.
OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the Investigator, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.
Time frame: up to 2.5 years from initial treatment
Duration of Response (DR)
DR was the time interval from the first complete response (CR) or partial response (PR) to the date of tumor progression or death from any cause, whichever was earlier. The duration of response was calculated only for those participants who achieved CR or PR.
Time frame: up to 2.5 years from initial treatment
Progression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC)
PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier.
Time frame: up to 2.5 years from initial treatment
Progression-free Survival (PFS) Time Assessed by the Investigator
PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors.
Time frame: up to 2.5 years from initial treatment
Overall Survival (OS)
OS was the time interval between registration to the date of death from any cause. The median time for OS was estimated from Kaplan-Meier Plots. A participant was to be censored for the OS analysis if the participant was alive by the study cut-off date. The censoring date was either the date that the participant was last known to be alive or the date of study cut-off, whichever came earlier.
Time frame: up to 2.5 years from initial treatment
Heath-related Quality of Life (QOL) Measured Via the Lung Cancer Subscale
HRQL was assessed with the Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) questionnaire, which was completed by the participants on Day 1 of Cycle 1 only (for baseline value), then on Day 14 of each even-numbered cycle to evaluate the participants symptoms. The questionnaire scored 7 symptoms: shortness of breath, weight loss, clarity in thinking, coughing, appetite, chest tightness, ease of breathing, on a 0-4 scale. The total FACT-LCS score ranged from 0-28 (where 28 was related to the worst outcome). To calculate a change, the baseline score was subtracted from the score obtained after treatment. A negative value implied an improvement in HRQL.
Time frame: Baseline to 2.5 years
Overall Safety - Number of Participants With Adverse Events
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
Time frame: up to 60+/-5 days after treatment discontinuation, or or until TEAE was resolved or stabilized (Collected till 18 July 2008)
Number of Participants With Laboratory Abnormalities
Participants with abnormal laboratory results for * Liver and renal function (Alkaline phosphatase, Alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], Creatinine, Hyperbilirubinemia), * Electrolytes (Hypercalcemia, Hypocalcemia, Hypokalemia, Hypernatremia, Hyponatremia, Hypophosphatemia) * Metabolism (Hypoalbuminemia, Hyperglycemia, Hypoglycemia) * Hematology (Partial thromboplastin time, Anemia, Lymphopenia, Neutropenia, Thrombocytopenia, Leukopenia)
Time frame: Up to 2.5 years
Peak of Free Aflibercept (VEGF Trap)
Plasma free aflibercept levels after the first aflibercept infusion were estimated by a validated direct measured by enzyme-linked immunosorbent assay (ELISA), with a limit of quantification (LOQ) of 15.6 ng/mL.
Time frame: Day 1 of the first infusion of Aflibercept (cycle 1)
Free and VEGF-bound Trough Aflibercept Concentrations (VEGF Trap)
Median free and VEGF-bound trough concentrations were determined at the end of each cycle beyond Cycle 2 (Steady-state) for each participant. Plasma free aflibercept levels were estimated by a validated direct ELISA, with an LOQ of 15.6 ng/mL. Plasma VEGF-bound aflibercept levels were also estimated by a separate validated direct ELISA with an LOQ of 43.9 ng/mL. Mean ± SD (coefficient of variation \[CV%\]) values were estimated from the median values calculated for each participant.
Time frame: At the end of each treatment cycle (up to 2.5 years)
Number of Participants With Anti-drug Antibodies
Anti-drug antibodies in a participant's serum sample were assayed with an anti-drug ELISA assay, with a lower limit of quantitation of 238.4 ng/mL for an undiluted human serum sample. Serum for anti-drug antibody analysis was collected pre-dose on every fourth cycle after Cycle 1 Day 1 (at 8 week intervals), at end of treatment (EOT), and during post-treatment follow-up 60 days after the last dose.
Time frame: up to 2.5 years after initial treatment
98 participants were registered into the study, of whom, 96 were exposed to study treatment.
| Milestone | Aflibercept 4.0 mg/kg |
|---|---|
| Started | 98 |
| Treated | 96 |
| Ongoing treatment | 2 |
| Completed | 0 |
| Not completed | 98 |
| Withdrew: Disease progression / lack of efficacy | 51 |
| Withdrew: Adverse event | 19 |
| Withdrew: Participant's request | 9 |
| Withdrew: Symptomatic / clinical progression | 11 |
| Withdrew: Clinical deterioration / death | 2 |
| Withdrew: General decline | 1 |
| Withdrew: Pneumonia | 1 |
| Withdrew: Did not take study medication | 2 |
| Withdrew: Ongoing treatment | 2 |
OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the IRC, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.
| Participants | Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST | Aflibercept 4.0 mg/kg Arm Assessed by RECIST |
|---|---|---|
| Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). | 0 | 0 |
DR was the time interval from the first complete response (CR) or partial response (PR) to the date of tumor progression or death from any cause, whichever was earlier. The duration of response was calculated only for those participants who achieved CR or PR.
No measurements were reported for this outcome.
PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier.
| weeks | Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST | Aflibercept 4.0 mg/kg Arm Assessed by RECIST |
|---|---|---|
| Progression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC) | 11.3 (9.3 to 16.1) | 11.3 (9.3 to 16.1) |
PFS time was interval from the date of registration to the date of tumor progression (by RECIST or modified RECIST), or death from any cause, whichever was earlier. If a participant did not progress or die, the date was censored to the date of last valid tumor assessment or the date of data cut-off, whichever was earlier. Median PFS time was estimated from Kaplan-Meier Plots. Progression was at least a 20% increase in the sum of the longest diameter (LD) of tumors, compared to smallest sum LD recorded since treatment started, or the appearance of one or more new tumors.
| weeks | Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST | Aflibercept 4.0 mg/kg Arm Assessed by RECIST |
|---|---|---|
| Progression-free Survival (PFS) Time Assessed by the Investigator | 12.0 (10.0 to 16.0) | 11.9 (9.7 to 14.7) |
OS was the time interval between registration to the date of death from any cause. The median time for OS was estimated from Kaplan-Meier Plots. A participant was to be censored for the OS analysis if the participant was alive by the study cut-off date. The censoring date was either the date that the participant was last known to be alive or the date of study cut-off, whichever came earlier.
| months | Aflibercept 4.0 mg/kg |
|---|---|
| Overall Survival (OS) | 26.9 (21.0 to 49.3) |
HRQL was assessed with the Functional Assessment of Cancer Therapy-Lung Cancer Subscale (FACT-LCS) questionnaire, which was completed by the participants on Day 1 of Cycle 1 only (for baseline value), then on Day 14 of each even-numbered cycle to evaluate the participants symptoms. The questionnaire scored 7 symptoms: shortness of breath, weight loss, clarity in thinking, coughing, appetite, chest tightness, ease of breathing, on a 0-4 scale. The total FACT-LCS score ranged from 0-28 (where 28 was related to the worst outcome). To calculate a change, the baseline score was subtracted from the score obtained after treatment. A negative value implied an improvement in HRQL.
| score on a scale | Aflibercept 4.0 mg/kg |
|---|---|
| Baseline FACT-LCS Score (N=83) | 19.9 ± 3.9 |
| Change from baseline at Cycle 2 (N=58) | -1.5 ± 3.6 |
| Change from baseline at Cycle 4 (N=41) | -1.9 ± 4.7 |
| Change from baseline at Cycle 6 (N=25) | -1.0 ± 5.0 |
| Change from baseline at Cycle 8 (N=13) | -1.4 ± 4.7 |
| Change from baseline at Cycle 10 (N=10) | -1.7 ± 6.9 |
| Change from baseline to last assessment (N=70) | -3.3 ± 5.2 |
All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 60 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.
| participants | Aflibercept 4.0 mg/kg |
|---|---|
| With any TEAE | 96 |
| With any Serious TEAE | 47 |
| With any TEAE leading to Death | 16 |
| with any TEAE leading to Treatment discontinuation | 19 |
Participants with abnormal laboratory results for * Liver and renal function (Alkaline phosphatase, Alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], Creatinine, Hyperbilirubinemia), * Electrolytes (Hypercalcemia, Hypocalcemia, Hypokalemia, Hypernatremia, Hyponatremia, Hypophosphatemia) * Metabolism (Hypoalbuminemia, Hyperglycemia, Hypoglycemia) * Hematology (Partial thromboplastin time, Anemia, Lymphopenia, Neutropenia, Thrombocytopenia, Leukopenia)
| Participants | Aflibercept 4.0 mg/kg |
|---|---|
| LIVER AND RENAL FUNCTION- Alkaline Phosphatase | 39 |
| LIVER AND RENAL FUNCTION - ALT | 35 |
| LIVER AND RENAL FUNCTION - AST | 37 |
| LIVER AND RENAL FUNCTION - Creatinine | 15 |
| LIVER AND RENAL FUNCTION - Hyperbilirubinemia | 4 |
| ELECTROLYTES - Hypercalcemia | 6 |
| ELECTROLYTES - Hypocalcemia | 15 |
| ELECTROLYTES - Hyperkalemia | 24 |
| ELECTROLYTES - Hypokalemia | 10 |
| ELECTROLYTES - Hypernatremia | 5 |
| ELECTROLYTES - Hyponatremia | 41 |
| ELECTROLYTES - Hypophosphatemia (N=91) | 14 |
| METABOLISM - Hypoalbuminemia (N=91) | 44 |
| METABOLISM - Hyperglycemia | 81 |
| METABOLISM - Hypoglycemia | 10 |
| HEMATOLOGY - Partial thromboplastin time (N=81) | 30 |
| HEMATOLOGY - Anemia | 34 |
| HEMATOLOGY - Lymphopenia (N=84) | 60 |
| HEMATOLOGY - Neutropenia (N=78) | 4 |
| HEMATOLOGY - Thrombocytopenia | 11 |
| HEMATOLOGY - Leukopenia | 11 |
Plasma free aflibercept levels after the first aflibercept infusion were estimated by a validated direct measured by enzyme-linked immunosorbent assay (ELISA), with a limit of quantification (LOQ) of 15.6 ng/mL.
| micrograms/mL | Aflibercept 4.0 mg/kg |
|---|---|
| Peak of Free Aflibercept (VEGF Trap) | 71.4 ± 31.8 |
Median free and VEGF-bound trough concentrations were determined at the end of each cycle beyond Cycle 2 (Steady-state) for each participant. Plasma free aflibercept levels were estimated by a validated direct ELISA, with an LOQ of 15.6 ng/mL. Plasma VEGF-bound aflibercept levels were also estimated by a separate validated direct ELISA with an LOQ of 43.9 ng/mL. Mean ± SD (coefficient of variation \[CV%\]) values were estimated from the median values calculated for each participant.
| micrograms/mL | Aflibercept 4.0 mg/kg |
|---|---|
| Trough free aflibercept concentration | 9.53 ± 6.28 |
| Trough VEGF-bound aflibercept concentration | 3.48 ± 1.04 |
OR was either complete response (CR) or partial response (PR) based on RECIST or modified RECIST. CR was the disappearance of all target/nor-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD (According to modified RECIST, to calculate LD for cavitated lesions, the longest cavitation diameters were subtracted from the LD of cavitated target lesions). Assessments were made by the Investigator, and confirmed by repeat tumor imaging 4-6 weeks after documentation of the initial response.
| participants | Aflibercept 4.0 mg/kg Arm Assessed by Modified RECIST | Aflibercept 4.0 mg/kg Arm Assessed by RECIST |
|---|---|---|
| Objective response (OR) | 2 | 2 |
| Complete response (CR) | 0 | 0 |
| Partial response (PR) | 2 | 2 |
Anti-drug antibodies in a participant's serum sample were assayed with an anti-drug ELISA assay, with a lower limit of quantitation of 238.4 ng/mL for an undiluted human serum sample. Serum for anti-drug antibody analysis was collected pre-dose on every fourth cycle after Cycle 1 Day 1 (at 8 week intervals), at end of treatment (EOT), and during post-treatment follow-up 60 days after the last dose.
| participants | Aflibercept 4.0 mg/kg |
|---|---|
| Number of Participants With Anti-drug Antibodies | 0 |
Collected over From treatment initiation to February 24, 2009.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 4 mg/kg | — | 48/96 (50%) | 93/96 (96.9%) |
| Event | 4 mg/kg |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/96 |
| Disease progressionGeneral disorders | 7/96 |
| PneumoniaInfections and infestations | 6/96 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/96 |
| Cardiac failure congestiveCardiac disorders | 2/96 |
| FatigueGeneral disorders | 2/96 |
| Non-cardiac chest painGeneral disorders | 2/96 |
| SepsisInfections and infestations | 2/96 |
| DehydrationMetabolism and nutrition disorders | 2/96 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/96 |
| Event | 4 mg/kg |
|---|---|
| FatigueGeneral disorders | 39/96 |
| HeadacheNervous system disorders | 38/96 |
| HypertensionVascular disorders | 38/96 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 37/96 |
| ConstipationGastrointestinal disorders | 27/96 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 27/96 |
| AnorexiaMetabolism and nutrition disorders | 24/96 |
| NauseaGastrointestinal disorders | 23/96 |
| CoughRespiratory, thoracic and mediastinal disorders | 22/96 |
| Oedema peripheralGeneral disorders | 20/96 |
| Age Continuous(years) | Aflibercept 4.0 mg/kg |
|---|---|
| Mean | 60.2 ± 11.0 |
| Sex: Female, Male(Participants) | Aflibercept 4.0 mg/kg |
|---|---|
| Female | 58 |
| Male | 40 |
| Race/Ethnicity, Customized(participants) | Aflibercept 4.0 mg/kg |
|---|---|
| Caucasian | 79 |
| Black | 3 |
| Asian, Oriental | 5 |
| Unknown or Not Reported | 11 |
The record gives a start of Jan 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 4 years 5 months after primary completion. A results delay was requested in Jul 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept